Regulus Therapeutics this week announced that it has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics against three exclusive targets.
The preclinical targets, Regulus said, are focused on cardiovascular and metabolic diseases and cancer. The company said its work on miR-33 for the treatment of atherosclerosis is included in the arrangement.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
